Autolus Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Autolus Therapeutics has a total shareholder equity of $111.5M and total debt of $170.9M, which brings its debt-to-equity ratio to 153.3%. Its total assets and total liabilities are $375.4M and $263.9M respectively.
Key information
153.3%
Debt to equity ratio
US$170.90m
Debt
| Interest coverage ratio | n/a |
| Cash | US$239.57m |
| Equity | US$111.47m |
| Total liabilities | US$263.91m |
| Total assets | US$375.38m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6A3A's short term assets ($275.3M) exceed its short term liabilities ($44.7M).
Long Term Liabilities: 6A3A's short term assets ($275.3M) exceed its long term liabilities ($219.2M).
Debt to Equity History and Analysis
Debt Level: 6A3A has more cash than its total debt.
Reducing Debt: 6A3A's debt to equity ratio has increased from 0% to 153.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6A3A has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 6A3A has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.